DSS announces business combination with Zoar Limited
The company highlights the merger as a strategy for creating shareholder value within the impact biomedical sector.
See the latest news and media coverage for DSS. We track all announcements, press releases, and industry mentions in real time, all in one place.
Diversified holding company
dssworld.comLast updated
In short: DSS reported a going concern opinion, named a new interim CEO, and advanced its Impact BioMedical spinoff.
The company highlights the merger as a strategy for creating shareholder value within the impact biomedical sector.
The company evaluates capital alternatives and remains committed to shareholder value creation.
The qualification was included in its fiscal 2025 annual report filed March 31, 2026, disclosed per NYSE rules.
The spin-out increases visibility and value, now pursuing a reverse merger.
On September 15, 2026, Alset Inc. entered into a securities purchase agreement with DSS Inc., acquiring for $500,000 a demand convertible promissory note bearing 3...
DSS, Inc. (NYSE American: DSS) ("DSS" or the "Company") today announced that Zoar Limited ("Zoar" or "PubCo") has filed a Registration Statement on Form F-4...
Aegis Capital Corp. is acting as the sole book-running manager for the offering on a firm commitment basis.
Shareholders of Record on July 10, 2023 to Receive Four Shares of Impact Biomedical Inc. for Every One Share of DSS, Inc. on a Future...
Track DSS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to DSS and other trending companies.